clinical trial

[키워드] 1:1 Administered administration Admission age allergy anti-IL6 anti-IL6 inhibitor antibody approved ARDS assigned AST/ALT authority baseline Blinding block Blood Brescia caused changed clinical clinical follow-up Clinical practice clinical trial concealed conducted consequence control arm control group Corticosteroids COVID COVID-19 COVID-19 infected patient COVID-19 infected patients COVID-19 patients CRP cytokine release death dissemination dose early intervention early treatment eCRF effective Efficacy and safety element elements elevated End end point EudraCT evaluate Evidence experimental arm Face mask Final Follow-up hospital Hospitalized hospitalized patients hyperinflammation Hyperinflammatory syndrome hypersensitivity Hypothesis ICU ICU admission IL-6 IL6 immunosuppressive in some inflammatory markers inflammatory parameter inhibitor initial Injury interstitial pneumonia Intervention lactation LDH life-threatening Local lymphopenia mechanical ventilation Methylprednisolone multi organ failure nasal neutropenia Non-invasive number objective open label Open-label outcome Oxygen requirement Parallel Arm participant pathogen Patient patients performed Pneumonia positive RT-PCR Pregnancy PROC produced progression proportion protocol protocols provided pulmonary infiltrate Radiographic randomised randomised controlled trial randomization Randomly RCT receive Registration reported rescued Respiratory failure risk risk factor Sample size sarilumab SARS-CoV SARS-CoV-2 SAS Sepsis Serum ferritin severe COVID-19 severe COVID-19 disease severe interstitial pneumonia severe respiratory failure Spain Spanish SpO2 Standard Standard of care study drug Study protocol supplemental oxygen therapeutic therapeutic intervention therapy Treatment treatment arm Treatment outcome Trial ULN use of corticosteroid Viral pneumonia virus website worsening
[DOI] 10.1186/s13063-020-04633-3 PMC 바로가기 [Article Type] Letter